G. Bosl

R. Motzer, G. Bosl, D. Feldman, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reply to S. Stenning et al and J. Lipshitz

G. Bosl, S. Patil, 2011 .

A pilot study of cisplatin‐vinblastine as the initial treatment of advanced head and neck cancer

R. Spiro, E. Strong, J. Shah, 1986, Cancer.

Mediastinal growing teratoma syndrome.

M. Burt, G. Bosl, H. Y. Afifi, 1997, The Annals of thoracic surgery.

Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy.

G. Bosl, D. Panicek, R. Heelan, 1990, Radiology.

Does size matter? Association between number of patients treated and patient outcome in metastatic testicular cancer.

E. Feuer, G. Bosl, J. Sheinfeld, 1999, Journal of the National Cancer Institute.

Pulmonary metastasectomy for testicular germ cell tumors: a 28-year experience.

V. Rusch, M. Bains, M. Burt, 1998, The Annals of thoracic surgery.

Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers

R. Motzer, G. Bosl, D. Wood, 1992, Cancer.

Clinical stage I testis cancer: long-term outcome of patients on surveillance.

H. Thaler, W. Fair, G. Bosl, 1998, The Journal of urology.

Prognostic factors in metastatic germ cell tumors.

N. Geller, A. Horwich, L. Freedman, 1990, Progress in clinical and biological research.

Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1992, Cancer research.

Genetic analysis of germ cell tumors: current progress and future prospects.

E. Dmitrovsky, R. Motzer, R. Chaganti, 1991, Hematology/oncology clinics of North America.

Detection of preferential NRAS mutations in human male germ cell tumors by the polymerase chain reaction

V. Reuter, R. Chaganti, G. Bosl, 1990, Genes, chromosomes & cancer.

Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience.

R. Motzer, B. Carver, G. Bosl, 2016, Urology.

Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer

R. Spiro, E. Strong, J. Shah, 1996, Head & neck.

Clinical Relevance of the i(12p) Chromosome in Germ cell Tumors

R. Motzer, V. Reuter, R. Chaganti, 1994 .

Clinical and genetic features of human germ cell cancer.

E. Dmitrovsky, R. Chaganti, G. Bosl, 1990, Cancer surveys.

Clinical relevance of the i(12p) marker chromosome in germ cell tumors.

R. Motzer, V. Reuter, R. Chaganti, 1994, Journal of the National Cancer Institute.

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.

R. Motzer, M. Mazumdar, D. Bajorin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors

G. Bosl, W. Whitmore, P. Sogani, 1986, Cancer.

The management of the clinically positive neck as part of a larynx preservation approach.

E. Strong, J. Shah, D. Kraus, 1993, International journal of radiation oncology, biology, physics.

Recurrent Germ Cell Tumors: Let's Try to Cure Them All.

G. Bosl, 2016, Journal of oncology practice.

Double‐Blind, Placebo‐Controlled, Randomized Trial of Granulocyte‐Colony Stimulating Factor During Postoperative Radiotherapy for Squamous Head and Neck Cancer

J. Shah, M. Zelefsky, A. Vickers, 2006, Cancer journal.

Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy

L. Deangelis, G. Bosl, C. Grommes, 2011, Cancer.

The Management of Advanced Germ Cell Tumors in 2016: The Memorial Sloan Kettering Approach.

G. Bosl, D. Feldman, S. Funt, 2016, Oncology.

Chemotherapy for teratoma with malignant transformation.

P. Kantoff, R. Motzer, D. Bajorin, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of age on clinicopathological outcomes and recurrence‐free survival after the surgical management of nonseminomatous germ cell tumour

B. Carver, G. Bosl, J. Sheinfeld, 2012, BJU international.

Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors.

R. Motzer, W. Fair, G. Bosl, 1992, The Journal of urology.

Residual mass: an indication for further therapy in patients with advanced seminoma following systemic chemotherapy.

R. Motzer, W. Fair, G. Bosl, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors

D. Bajorin, G. Bosl, A. Aprikian, 1994, Cancer.

Residual mass after chemotherapy for seminoma: changing concepts of management.

G. Bosl, H. Herr, 1987, The Journal of urology.

Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy.

R. Motzer, D. Bajorin, G. Bosl, 1993, Journal of the National Cancer Institute.

A review of the management of germ cell tumors: evolution of a curative treatment program.

G. Bosl, N. Iannotti, 1990, Cancer investigation.

Abnormalities of 2q: A common genetic link between rhabdomyosarcoma and hepatoblastoma?

V. Reuter, C. Mies, R. Chaganti, 1991, Genes, chromosomes & cancer.

Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells.

S. Heath, R. Chaganti, G. Bosl, 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors

J. Bacik, V. Reuter, M. Mansukhani, 2004, Molecular Cancer.

Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.

P. Kantoff, G. Demetri, C. Bokemeyer, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Status and prospects of the treatment of disseminated germ-cell tumors

G. Bosl, 1984, World Journal of Urology.

Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis.

M. Burt, R. Motzer, D. Bajorin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.

R. Motzer, A. Vickers, B. Carver, 2006, The Journal of urology.

VAB-6 as initial treatment of patients with advanced seminoma.

G. Bosl, W. Whitmore, P. Sogani, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic chemotherapy in the management of bladder cancer.

G. Bosl, D. Nanus, 1989, Cancer treatment and research.

Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

V. Reuter, H. Scher, D. Dershaw, 1988, The Journal of urology.

Acute chest pain syndrome during bleomycin infusions.

M. Kris, G. Bosl, L. Schwartzberg, 1987, Cancer.

Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.

G. Bosl, N. Vogelzang, B. Kennedy, 1981, Annals of internal medicine.

Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis.

V. Reuter, R. Chaganti, G. Bosl, 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors.

R. Motzer, M. Voss, G. Bosl, 2011, Hematology/oncology clinics of North America.

Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.

J. Bacik, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) and bladder preservation.

V. Reuter, H. Scher, C. Sternberg, 1990, Progress in clinical and biological research.

Well-differentiated peripheral cholangiocarcinoma with an unusual clinical course.

G. Bosl, D. Kiang, E. Foucar, 1979, Gastroenterology.

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.

L. Schwartz, R. Motzer, H. Scher, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.

R. Motzer, M. Mazumdar, D. Bajorin, 1993, Journal of the National Cancer Institute.

Sequential dose-intensive paclitaxel plus ifosfamide and carboplatin plus etoposide with autologous stem cell transplantation for germ cell tumor (GCT) patients (pts)

M. Bains, J. Bacik, R. Motzer, 2005 .

Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.

M. Bains, R. Motzer, J. Bacik, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen.

V. Reuter, H. Scher, C. Sternberg, 1989, British journal of urology.

Germ cell tumors: there is still plenty to learn.

G. Bosl, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.

R. Motzer, A. Vickers, D. Bajorin, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Controversies in the Management of Clinical Stage I Seminoma: Carboplatin a Decade in-Time to Start Backing Out.

S. Sleijfer, G. Bosl, D. Feldman, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin for stage I seminoma and the sword of Damocles.

G. Bosl, P. Loehrer, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.

J. Bacik, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.

J. Bacik, T. Mariani, M. Mazumdar, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery for a post-chemotherapy residual mass in seminoma.

R. Motzer, D. Bajorin, G. Bosl, 1997, The Journal of urology.

Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy

R. Motzer, M. Mazumdar, D. Bajorin, 1994, Cancer.

Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.

R. Motzer, S. Eggener, B. Carver, 2007, The Journal of urology.

Leukemic differentiation of a mediastinal germ cell tumor

M. Ladanyi, K. Offit, S. Jhanwar, 1989, Genes, chromosomes & cancer.

Platinum‐DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme‐linked immunosorbent assay

F. Perera, W. Tsai, R. Motzer, 1994, Cancer.

Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency

R. Motzer, H. Scher, G. Bosl, 2004, Cancer Chemotherapy and Pharmacology.

Carboplatin, etoposide, and bleomycin for patients with poor‐risk germ cell tumors

N. Geller, R. Motzer, H. Scher, 1990, Cancer.

Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors.

G. Bosl, J. Preibisz, J. Sealey, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vinblastine, bleomycin and cis-diamminedichloroplatinum in the treatment of advanced testicular carcinoma. Possible importance of longer induction and shorter maintenance schedules.

P. Lange, G. Bosl, J. Rosai, 1980, The American journal of medicine.

Re: Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.

M. Morris, G. Bosl, 2000 .

Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors.

M. Morris, G. Bosl, 2000, The Journal of urology.

Physical mapping of a commonly deleted region, the site of a candidate tumor suppressor gene, at 12q22 in human male germ cell tumors.

R. Kucherlapati, C. Falk, R. Chaganti, 1996, Genomics.

Germ cell tumors: unraveling a biological paradox.

R. Chaganti, G. Bosl, 1995, Laboratory investigation; a journal of technical methods and pathology.

Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1994, Oncogene.

Allelic loss and somatic differentiation in human male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1994, Oncogene.

Allelic deletions in the long arm of chromosome 12 identify sites of candidate tumor suppressor genes in male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Cytogenetic and molecular analysis of human male germ cell tumors: Chromosome 12 abnormalities and gene amplification

E. Dmitrovsky, M. Ladanyi, N. Geller, 1990, Genes, chromosomes & cancer.

Current perspectives on the role of adjunctive surgery in combined modality treatment for patients with germ cell tumors.

R. Motzer, D. Bajorin, G. Bosl, 1992, Seminars in oncology.

Clinical outcome and predictors of survival in late relapse of germ cell tumor.

R. Motzer, G. V. Kondagunta, S. Eggener, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor

R. Motzer, D. Bajorin, B. Carver, 2008, Cancer.

Clinical outcome following post‐chemotherapy retroperitoneal lymph node dissection in men with intermediate‐ and poor‐risk nonseminomatous germ cell tumour

R. Motzer, B. Carver, G. Bosl, 2007, BJU international.

Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors

G. V. Kondagunta, S. Eggener, B. Carver, 2007, Cancer.

Teratoma with malignant transformation in germ cell tumors in men

G. Bosl, T. Ahmed, S. Hajdu, 1985, Cancer.

Adjuvant surgery in the management of patients with germ cell tumors.

G. Bosl, 1984, The Annals of thoracic surgery.

Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.

M. Bains, J. Bacik, M. Mazumdar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of ifosfamide plus cisplatin‐based chemotherapy as salvage therapy for patients with refractory germ cell tumors

E. Dmitrovsky, N. Geller, P. Russo, 1990, Cancer.

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

N. Geller, J. Auman, H. Scher, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

R. Motzer, D. Sjoberg, D. Bajorin, 2015, Urology.

Clinical Outcome of Patients with Fibrosis/Necrosis at Post‐Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors

R. Motzer, D. Bajorin, B. Carver, 2015, The Journal of urology.

Outcomes After Multidisciplinary Management of Primary Mediastinal Germ Cell Tumors

David R. Jones, V. Rusch, M. Bains, 2020, Annals of surgery.

Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1996, Oncogene.

Analysis of chromosome 12 aneuploidy in interphase cells from human male germ cell tumors by fluorescence in situ hybridization

V. Reuter, R. Chaganti, G. Bosl, 1992, Genes, chromosomes & cancer.

Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.

R. Motzer, D. Bajorin, B. Carver, 2019, Urology.

Practice Makes Perfect: The Rest of the Story in Testicular Cancer as a Model Curable Neoplasm.

W. Lowrance, N. Hanna, T. Powles, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.

R. Motzer, M. Mazumdar, D. Bajorin, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.

R. Motzer, B. Carver, G. Bosl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.

R. Motzer, D. Bajorin, G. Bosl, 2005, The Journal of urology.

The management of patients with nonseminomatous germ cell tumors of the testis with serologic disease only after orchiectomy.

W. Fair, G. Bosl, H. Herr, 1994, The Journal of urology.

High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions.

R. Motzer, G. Bosl, 1992, Journal of the National Cancer Institute.

High‐dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated

P. Russo, R. Motzer, W. Fair, 1992, Cancer.

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.

N. Geller, M. Bains, N. Martini, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982).

N. Martini, G. Bosl, W. Whitmore, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors.

G. Bosl, W. Whitmore, N. Vogelzang, 1985, The American journal of medicine.

Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation

V. Reuter, R. Chaganti, G. Bosl, 1998, Oncogene.

Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors

R. Motzer, T. Mariani, D. Bajorin, 2000, Investigational New Drugs.

Abnormal colony formation and prostaglandin e responsiveness of myeloid progenitor cells in patients cured of germ cell neoplasms after combination chemotherapy

G. Bosl, L. Pelus, S. Leitner, 1987, Cancer.

Cytogenetic and immunohistochemical evidence for the germ cell origin of a subset of acute leukemias associated with mediastinal germ cell tumors.

M. Ladanyi, S. Jhanwar, R. Motzer, 1990, Journal of the National Cancer Institute.

Neuroendocrine (Merkel cell) carcinoma of the skin: A histologic and ultrastructural study of two cases

G. Bosl, J. Rosai, E. Foucar, 1980, The American journal of surgical pathology.

Reply to L.H. Einhorn et al

M. Bains, R. Motzer, G. Bosl, 2010 .

Salvage chemotherapy for patients with advanced pure seminoma.

J. Bacik, M. Mazumdar, V. Reuter, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

593: The Incidence and Implications of Disease Outside a Modified Template in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND) for Metastatic Non-Seminomatous Germ Cell Tumors (NSGCT)

R. Motzer, D. Bajorin, B. Carver, 2006 .

594: Incidence and Predictors of Disease Outside a Modified Retroperitoneal Lymph Node Dissection Template in Clinical Stage (CS) I-IIA Nonseminomatous Germ Cell Testicular Cancer

D. Parekh, S. Eggener, B. Carver, 2006 .

Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome.

J. Bacik, R. Motzer, D. Bajorin, 2003, Urology.

Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

R. Motzer, D. Bajorin, G. Bosl, 1992, Seminars in oncology.

Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor.

R. Motzer, D. Sjoberg, D. Bajorin, 2018, Urology.

Rare de novo germline copy-number variation in testicular cancer.

B. Yamrom, J. Kendall, A. Leotta, 2012, American journal of human genetics.

Intensive five‐drug combination chemotherapy for adult acute non‐lymphocytic leukemia

C. Bloomfield, G. Bosl, B. Peterson, 1980, Cancer.

Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features

J. Bacik, M. Mazumdar, V. Reuter, 2002, International journal of surgical pathology.

Primary retroperitoneal lymph node dissection in low-stage testicular germ cell tumors: a detailed pathologic study with clinical outcome analysis with special emphasis on patients who did not receive adjuvant therapy.

V. Reuter, S. Tickoo, S. Fine, 2013, Urology.

Intracardiac teratoma 15 years after treatment of a nonseminomatous germ cell tumor.

P. Russo, V. Reuter, G. Bosl, 1993, The Journal of urology.

Pituitary and testicular hormonal function after treatment for germ cell tumours.

G. Bosl, D. Bajorunas, 1987, International journal of andrology.

Gonadal dysfunction in patients treated for metastatic germ-cell tumors.

G. Bosl, D. Bajorunas, S. Leitner, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined modality treatment of locally advanced breast cancer: Adjuvant combination chemotherapy with and without doxorubicin

G. Bosl, E. Casper, D. Kinne, 2005, Breast Cancer Research and Treatment.

Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies.

E. Dmitrovsky, R. Motzer, V. Reuter, 1991, Journal of the National Cancer Institute.

Isochromosome 12p in non-seminoma cell lines: karyologic amplification of c-ki-ras2 without point-mutational activation.

E. Dmitrovsky, W. Miller, R. Chaganti, 1990, Oncogene.

Progression‐free and overall survival in patients with relapsed/refractory germ cell tumors treated with single‐agent chemotherapy: Endpoints for clinical trial design

R. Motzer, D. Bajorin, G. Bosl, 2012, Cancer.

Good Risk Chemotherapy Trials for Patients with Advanced Germ Cell Tumours: The MSKCC Experience

R. Motzer, R. Motzer, D. Bajorin, 1994 .

Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors.

R. Chaganti, G. Bosl, V. Murty, 1994, Cancer research.

Clinical outcomes of local and metastatic testicular sex cord-stromal tumors.

V. Reuter, R. Motzer, H. Al-Ahmadie, 2013, The Journal of urology.

The evolving role of chemotherapy of germ cell tumors.

R. Motzer, H. Scher, D. Bajorin, 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.

R. Motzer, M. Mazumdar, V. Reuter, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic analysis in the diagnosis of neoplasms of unknown primary tumor site.

R. Motzer, R. Chaganti, G. Bosl, 1993, Seminars in oncology.

Orchiectomy alone in the treatment of clinical stage I nonseminomatous germ cell tumor of the testis.

G. Bosl, W. Whitmore, P. Sogani, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Trimetrexate in Patients with Advanced Renal Cell Carcinoma

H. Scher, C. Sternberg, G. Bosl, 1989 .

Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.

H. Scher, C. Sternberg, G. Bosl, 1989, European journal of cancer & clinical oncology.

C. Cordon-Cardo, R. Motzer, V. Reuter, 1988, Cancer research.

ID gene expression varies with lineage during differentiation of pluripotential male germ cell tumor cell lines

V. Reuter, R. Chaganti, G. Bosl, 2001, Cell and Tissue Research.

Nonrandom chromosome abnormalities in testicular and ovarian germ cell tumor cell lines.

E. Dmitrovsky, R. Chaganti, G. Bosl, 1990, Cancer genetics and cytogenetics.

Current status of larynx preservation with multimodality therapy.

E. Strong, G. Bosl, D. Pfister, 1992, Oncology.

Germ cell tumor clinical trials in North America.

G. Bosl, 1999, Seminars in surgical oncology.

Serum tumor markers and patient allocation to good‐risk and poor‐risk clinical trials in patients with germ cell tumors

N. Geller, D. Bajorin, G. Bosl, 1991, Cancer.

Improved control of cisplatin‐induced emesis with high‐dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients

S. Groshen, M. Kris, G. Bosl, 1985, Cancer.

Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma.

R. Motzer, G. Bosl, J. Sheinfeld, 2003, Urology.

Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.

R. Motzer, D. Kraus, D. Bajorin, 2010, Urology.

Two‐drug therapy in patients with metastatic germ cell tumors

N. Geller, D. Bajorin, G. Bosl, 1991, Cancer.

Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum.

M. Bains, R. Motzer, J. Bacik, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel, I fosfamide, a nd C isplatin S econd-Line T herapy for P atients W ith R elapsed T esticular G erm C ell C ancer

M. Bains, R. Motzer, J. Bacik, 2000 .

High‐dose chemotherapy as primary treatment for poor‐risk germ‐cell tumors: The Memorial Sloan‐Kettering experience (1988–1999)

M. Morris, G. Bosl, 1999, International journal of cancer.

Serum Tumor Markers in Patients with Metastatic Germ Cell Tumors of the Testis A IO-Year Experience

G. Bosl, 2003 .

Serum tumor markers in patients with metastatic germ cell tumors of the testis. A 10-year experience.

N. Geller, G. Bosl, W. Whitmore, 1983, The American journal of medicine.

Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

N. Geller, H. Scher, G. Bosl, 1983, Cancer research.

Interrelationships of histopathology and other clinical variables in patients with germ cell tumors of the testis

N. Geller, G. Bosl, W. Whitmore, 1983, Cancer.

Tumor markers in advanced nonseminomatous testicular cancer

P. Lange, G. Bosl, J. Rosai, 1981, Cancer.

Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer

T. Waldmann, P. Lange, G. Bosl, 1981, Cancer.

Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors.

R. Motzer, M. Mazumdar, V. Reuter, 1998, The Journal of urology.

Surgery of Testicular Tumors

G. Bosl, J. Sheinfeld, 2012 .

Reoperative RPLND for germ cell tumor; initial presentation, complications and outcome

J. Bacik, R. Motzer, D. Bajorin, 2001 .

Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate

M. Kris, G. Bosl, E. Casper, 2005, Journal of Cancer Research and Clinical Oncology.

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors

H. Scher, D. Bajorin, C. Sternberg, 1991, Cancer.

Sporothrix schenckii meningitis in a farmer with Hodgkin's disease.

G. Bosl, P. Peterson, G. Ewing, 1980, The American journal of medicine.

Salvage Laryngectomy for Unsuccessful Larynx Preservation Therapy

R. Spiro, E. Strong, J. Shah, 1995, The Annals of otology, rhinology, and laryngology.

Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors.

N. Geller, G. Bosl, J. Nisselbaum, 1990, Cancer research.

Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma.

P. Scardino, W. Catalona, P. Lange, 1980, The Journal of urology.

Human chorionic gonadotropin and alphafetoprotein in the staging of nonseminomatous testicular cancer

T. Waldmann, P. Lange, G. Bosl, 1981, Cancer.

Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors.

A. Olshen, V. Reuter, J. Korkola, 2006, Cancer research.

The future of therapy for nonseminomatous germ cell tumors.

G. Bosl, George J Bosl, Alessia C Donadio, 2002, Chest surgery clinics of North America.

Testicular germ-cell cancer.

R. Motzer, G. Bosl, 1997, The New England journal of medicine.

The Origin of Non-Germ Cell Tumour Elements within Germ Cell Tumours and Midline Tumours of Uncertain Histogenesis

R. Motzer, R. Chaganti, G. Bosl, 1994 .

Molecular Genetics in Germ Cell Tumours

P. H. Rao, R. Chaganti, G. Bosl, 1994 .

Cytogenetics of male germ-cell tumors.

R. Chaganti, G. Bosl, E. Rodriguez, 1993, The Urologic clinics of North America.

International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

Richard Sylvester, Andrew Kramar, Madhu Mazumdar, 1997 .

Expression of ID Genes in Differentiated Elements of Human Male Germ Cell Tumors

V. Reuter, R. Chaganti, G. Bosl, 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features

N. Geller, G. Bosl, G. Toner, 1991, Cancer.

Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas

V. Reuter, S. Tickoo, S. Fine, 2009, Modern Pathology.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

R. Motzer, J. Bacik, M. Mazumdar, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

V. Vacic, N. Schultz, M. Berger, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors

V. Reuter, G. Iyer, H. Al-Ahmadie, 2014, Clinical Cancer Research.

Argument in favor of using mass units to calibrate and report concentrations of human choriogonadotropin.

G. Bosl, M. Schwartz, J. Nisselbaum, 1986, Clinical chemistry.

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

N. Geller, D. Bajorin, G. Bosl, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy trials in recurrent primary intracranial germ cell tumors

G. Bosl, Jeffrey C. Allen, R. Walker, 2005, Journal of Neuro-Oncology.

Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.

M. Mazumdar, R. Motzer, D. Bajorin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients.

R. Motzer, M. Mazumdar, D. Bajorin, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor classification and size in germ‐cell testicular cancer. Influence on the occurrence of metastases

P. Lange, G. Bosl, J. Rosai, 1982, Cancer.

Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors

E. Dmitrovsky, N. Geller, V. Reuter, 1989 .

Isochromosome of the short arm of chromosome 12: clinically useful markers for male germ cell tumors.

E. Dmitrovsky, N. Geller, V. Reuter, 1989, Journal of the National Cancer Institute.

Hemorrhage: a complication of metastatic testicular choriocarcinoma.

R. Motzer, G. Bosl, 1987, Urology.

VP‐16–213 and cisplatin in the treatment of patients with refractory germ cell tumors

G. Bosl, W. Whitmore, P. Sogani, 1984, American journal of clinical oncology.

Trlclonai Gammopathy In a Patient

G. Bosl, M. Schwartz, J. Nisselbaum, 2000 .

Malignant carcinoid of the gallbladder: Third reported case and review of the literature

G. Bosl, A. Yagoda, L. H. Câmara-Lopes, 1980, Journal of surgical oncology.

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.

N. Geller, J. Auman, G. Bosl, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in serum alpha-fetoprotein and chorionic gonadotropin in response to cancer therapy.

G. Bosl, R. Golbey, M. Schwartz, 1984, Annals of clinical and laboratory science.

Medical treatment of advanced testicular cancer.

R. Motzer, G. Bosl, D. Feldman, 2008, JAMA.

Salvage chemotherapy for patients with germ cell tumors. The memorial sloan‐kettering cancer center experience (1979–1989)

N. Geller, R. Motzer, P. Russo, 1991, Cancer.

Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.

R. Motzer, J. Bacik, M. Mazumdar, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification and management of poor risk patients with germ cell tumors: the Memorial Sloan-Kettering Cancer Center experience.

N. Geller, D. Bajorin, G. Bosl, 1988, Seminars in oncology.

Role of adjuvant chemotherapy in patients with stage II nonseminomatous germ-cell tumors.

R. Motzer, G. Bosl, 1993, The Urologic clinics of North America.

Bladder cancer: advances in biology and treatment.

C. Cordon-Cardo, V. Reuter, H. Scher, 1994, Critical reviews in oncology/hematology.

Optimal management of clinical stage I testis cancer: one size does not fit all.

G. Bosl, R. de Wit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-Intensive Chemotherapy in Patients with Germ Cell Tumours: The Memorial Sloan-Kettering Cancer Center Experience

R. Motzer, D. Bajorin, G. Bosl, 1994 .

Vinblastine, intermittent bleomycin, and single-dose cis-dichlorodiammineplatinum(II) in the management of stge III testicular cancer.

P. Lange, G. Bosl, B. Kennedy, 1980, Cancer treatment reports.

Stage migration and the increasing proportion of complete responders in patients with advanced germ cell tumors.

N. Geller, G. Bosl, E. Chan, 1988, Cancer research.

Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.

R. Motzer, M. Mazumdar, D. Bajorin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The treatment of extragonadal seminoma.

M. Bains, G. Bosl, W. Whitmore, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IMPACT OF DELAY IN DIAGNOSIS ON CLINICAL STAGE OF TESTICULAR CANCER

P. Lange, G. Bosl, N. Vogelzang, 1981, The Lancet.

Advances in the Understanding of Germ Cell Tumour Biology

R. Chaganti, G. Bosl, J. Houldsworth, 2002 .

Analysis of chromosome 12 abnormalities in male germ cell cancers.

E. Dmitrovsky, N. Geller, V. Reuter, 1991, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.

R. Motzer, M. Mazumdar, D. Bajorin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors.

N. Geller, G. Bosl, H. Herr, 1991, European urology.

Advanced Seminoma: The Role of Chemotherapy and Adjunctive Surgery

N. Geller, R. Motzer, W. Fair, 1988, Annals of Internal Medicine.

Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.

M. Bains, R. Motzer, T. Mariani, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial

E. Dmitrovsky, R. Motzer, H. Scher, 1993, Cancer.

Sarcoidosis, "Sarcoid-like lymphadenopathy," and testicular germ cell tumors.

G. Bosl, G. Toner, 1990, The American journal of medicine.

Transcriptional program of bone morphogenetic protein-2-induced epithelial and smooth muscle differentiation of pluripotent human embryonal carcinoma cells

A. Olshen, R. Chaganti, G. Bosl, 2005, Functional & Integrative Genomics.

Decompression of epidural metastases from germ cell tumors with chemotherapy

G. Krol, D. Bajorin, G. Bosl, 1990, Journal of Neuro-Oncology.

Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent.

J. Shah, E. Venkatraman, M. Zelefsky, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas.

J. Shah, C. Cordon-Cardo, A. Stoffel, 2002, The American journal of pathology.

Carboplatin in clinical stage I seminoma: too much and too little at the same time.

G. Bosl, S. Patil, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors.

Li-Xuan Qin, Victor E Reuter, A. Olshen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How We Care for an Older Patient With Cancer.

G. Bosl, A. Shahrokni, B. Korc-Grodzicki, 2017, Journal of oncology practice.

Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

R. Motzer, V. Reuter, S. Tickoo, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor.

B. Taylor, C. Iacobuzio-Donahue, V. Reuter, 2020, The Journal of clinical investigation.

TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.

M. Bains, R. Motzer, D. Bajorin, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma germ cell tumor.

J. Bacik, M. Mazumdar, V. Reuter, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.

V. Reuter, R. Motzer, N. Palanisamy, 1998, Cancer research.

Telomerase activity in germ cell cancers and mature teratomas.

Monika Engelhardt, Ethan Dmitrovsky, E. Dmitrovsky, 1999, Journal of the National Cancer Institute.

Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.

R. Motzer, D. Bajorin, G. Bosl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse.

R. Motzer, V. Reuter, D. Bajorin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity.

H. Hricak, L. Schwartz, G. Bosl, 2011, Radiology.

Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs.

C. Bourque, B. Taylor, A. Viale, 2020, JCO precision oncology.

Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.

J. Bacik, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.

R. Motzer, M. Mazumdar, D. Bajorin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.

E. Feuer, N. Geller, G. Bosl, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for relapse after complete response in patients with metastatic germ cell tumors

N. Geller, G. Bosl, Eva Y. W. Chan, 1989, Cancer.

Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer.

N. Geller, H. Scher, G. Bosl, 1988, Cancer research.

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors

R. Motzer, V. Reuter, D. Bajorin, 2021, The oncologist.

Replication error-type genetic instability at 1q42-43 in human male germ cell tumors.

V. Reuter, R. Chaganti, G. Bosl, 1994, Cancer research.

Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT

R. Motzer, G. Bosl, B. Murphy, 1992, Investigational New Drugs.

Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.

R. Motzer, T. Chou, G. Bosl, 1994, Journal of the National Cancer Institute.

Mechanism and Role of SOX2 Repression in Seminoma: Relevance to Human Germline Specification

A. Califano, J. Korkola, V. Thodima, 2016, Stem cell reports.

Phase II trial of Didemnin B in patients with advanced renal cell carcinoma

R. Motzer, H. Scher, C. Sternberg, 1990, Investigational new drugs.

Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.

M. Kattan, R. Motzer, D. Bajorin, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective phase ii trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck

R. Spiro, E. Strong, J. Shah, 1998, Head & neck.

Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer.

R. Spiro, E. Strong, J. Shah, 1991, International journal of radiation oncology, biology, physics.

Very-high-dose cisplatin with bleomycin infusion as initial treatment of advanced head and neck cancer.

R. Spiro, E. Strong, J. Shah, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemotherapy in the management of stage III and IV tumors of the head and neck

G. Bosl, 1983, Ca.

Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.

R. Motzer, M. Mazumdar, G. Bosl, 1993, Cancer research.

A 3-Mb high-resolution BAC/PAC contig of 12q22 encompassing the 830-kb consensus minimal deletion in male germ cell tumors.

R. Kucherlapati, K. Montgomery, R. Chaganti, 1999, Genome research.

Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.

S. Fosså, G. Bosl, J. Gietema, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of mitoguazone in patients with advanced head and neck cancer.

R. Wittes, N. Geller, S. Thongprasert, 1984, Cancer treatment reports.

A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma.

E. Gilboa, V. Reuter, N. Bander, 1992, Human gene therapy.

Weighing risks and benefits of postchemotherapy retroperitoneal lymph node dissection: not so easy.

R. Motzer, G. Bosl, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

590: Viable Germ Cell Tumor (GCT) Identified at Post-Chemotherapy Retroperitoneal Lymph Node Dissection (PC-RPLND): The Significance of Risk Assignment and Adjuvant Chemotherapy

A. Vickers, B. Carver, G. Bosl, 2006 .

Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.

R. Motzer, B. Carver, G. Bosl, 2012, Urology.

Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.

R. Motzer, D. Bajorin, B. Carver, 2006, Urology.

The current status of salvage chemotherapy for patients with cisplatin-resistant germ cell tumors.

R. Motzer, G. Bosl, 1993, Cancer investigation.

Phase II trial of carboplatin in patients with advanced germ cell tumors refractory to cisplatin.

R. Motzer, G. Bosl, R. Golbey, 1987, Cancer treatment reports.

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

R. Motzer, G. Bosl, M. Ginsberg, 2010, Investigational New Drugs.

Advances in urologic oncology: results progress from successful interdisciplinary research.

R. Motzer, D. Bajorin, G. Bosl, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

M. Bains, R. Motzer, D. Bajorin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin‐based Chemotherapy: Application of the Framingham Risk Score

R. Frisina, S. Fosså, M. Dolan, 2018, Clinical genitourinary cancer.

Phase III trial of conventional-dose chemotherapy alone or with high-dose chemotherapy for metastatic germ cell tumors (GCT) patients (PTS): A cooperative group trial by Memorial Sloan-Kettering Cancer Center, ECOG, SWOG, and CALGB.

M Mazumdar, R. Motzer, J. Bacik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic germ cell tumors: modeling for response to chemotherapy.

R. Motzer, M. Mazumdar, D. Bajorin, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continued refinement in the treatment of germ cell tumour patients.

D. Bajorin, G. Bosl, 1991, European journal of cancer.

Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors.

R. Motzer, V. Reuter, D. Bajorin, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma: Treatment Results, Pharmacokinetics, and Tumor Growth Factor Expression1

R. Motzer, V. Reuter, H. Scher, 2006 .

Phase II Trial of Suramin in Patients with Advanced Renal Cell Carcinoma : Treatment Results , Pharmacokinetics , and Tumor Growth Factor Expression 1

R. Motzer, V. Reuter, H. Scher, 2006 .

Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer.

E. Strong, J. Shah, R. Motzer, 1994, Archives of Otolaryngology - Head and Neck Surgery.

Bleomycin in germ cell tumor therapy: not all regimens are created equal.

D. Bajorin, G. Bosl, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Larynx Preservation with Combined Chemotherapy and Radiation Therapy in Advanced Hypopharynx Cancer

R. Spiro, E. Strong, J. Shah, 1994, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Acute chest pain syndrome during bleomycin infusions

M. Kris, G. Bosl, L. Schwartzberg, 1987 .

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

H. Scher, D. Bajorin, W. Fair, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

M. Bains, R. Motzer, D. Bajorin, 2015, Clinical genitourinary cancer.

Development of a risk stratification system to guide treatment for female germ cell tumors.

G. Bosl, D. Feldman, C. Aghajanian, 2015, Gynecologic oncology.

Thoracic Metastasectomy in Germ Cell Tumor Patients Treated with First-Line Versus Salvage.

David R. Jones, M. Bains, V. Reuter, 2020, The Annals of thoracic surgery.

The management of patients with advanced germ cell tumors. Seminoma and nonseminoma.

R. Motzer, D. Bajorin, G. Bosl, 1994, The Urologic clinics of North America.

Development and Validation of a Gene-Based Model for Outcome Prediction in Germ Cell Tumors Using a Combined Genomic and Expression Profiling Approach

A. Olshen, V. Reuter, J. Korkola, 2015, PloS one.

Personalized Medicine and Imaging Presence of Somatic Mutations within PIK 3 CA , AKT , RAS , and FGFR 3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors

V. Reuter, G. Iyer, H. Al-Ahmadie, 2014 .

Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.

R. Motzer, D. Bajorin, B. Carver, 2015, The Journal of urology.

The effect of a 7‐day delay in chemotherapy cycles on complete response and event‐free survival in good‐risk disseminated germ cell tumor patients

N. Geller, R. Motzer, G. Bosl, 1990, Cancer.

Management of Unresectable Malignant Tumors at the Skull Base Using Concomitant Chemotherapy and Radiotherapy with Accelerated Fractionation

E. Strong, J. Shah, M. Zelefsky, 1994, Skull base surgery.

Phase I trial of escalating doses of cisplatin in hypertonic saline.

D. Bajorin, G. Bosl, R. Fein, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Trial of Etoposide + Cisplatin Versus Vinblastine + Bleomycin + Cisplatin + Cyclophosphamide + Dactinomycin in Patients with Good-Prognosis Germ Cell Tumors

N. Geller, J. Auman, H. Scher, 1989 .

Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis.

R. Motzer, D. Bajorin, G. Bosl, 2003, The Journal of urology.

Germ Cell Tumours: Past, Present and Future

E. Dmitrovsky, R. Chaganti, G. Bosl, 1994 .

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

R. Motzer, V. Reuter, B. Costello, 2018 .

The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome Following Chemotherapy for Metastatic Testicular Cancer

R. Motzer, S. Eggener, B. Carver, 2013 .

Chemotherapy f or T eratoma W ith M alignant T ransformation

P. Kantoff, R. Motzer, D. Bajorin, 2003 .

Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline.

D. Bajorin, G. Bosl, D. Niedzwiecki, 1986, Cancer research.

Combined-modality therapy for bladder cancer.

H. Scher, D. Bajorin, G. Bosl, 1997, Oncology.

Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection.

V. Reuter, R. Motzer, R. Thompson, 2012, Urology.

Altered renin and aldosterone excretion in patients treated for metastatic germ cell tumours.

G. Bosl, J. Preibisz, J. Sealey, 1987, International journal of andrology.

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

M. Gonen, M. Shah, G. Schwartz, 2009, Clinical Cancer Research.

Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors

R. Motzer, G. V. Kondagunta, G. Bosl, 2007, Investigational New Drugs.

Hormone-secreting metastatic interstitial cell tumor of the testis.

P. Russo, G. Bosl, W. Whitmore, 1989, The Journal of urology.

566 EVALUATION OF LYMPH NODE COUNTS IN PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION

V. Reuter, R. Motzer, R. Thompson, 2010 .

Contemporary lymph node counts during primary retroperitoneal lymph node dissection.

V. Reuter, R. Motzer, R. Thompson, 2011, Urology.

Detection and analysis of origin of i(12p), a diagnostic marker of human male germ cell tumors, by fluorescence in situ hybridization

V. Reuter, R. Chaganti, G. Bosl, 1991, Genes, chromosomes & cancer.

Molecular events in germ cell tumours: linking chromosome‐12 gain, acquisition of pluripotency and response to cisplatin

J. Korkola, R. Chaganti, G. Bosl, 2009, BJU international.

The use of tumor markers in germ cell malignancies.

R. Chaganti, G. Bosl, 1994, Hematology/oncology clinics of North America.

Constitutive Gene Expression Predisposes Morphogen‐Mediated Cell Fate Responses of NT2/D1 and 27X‐1 Human Embryonal Carcinoma Cells

A. Olshen, J. Korkola, R. Chaganti, 2007, Stem cells.

Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors.

R. Motzer, R. Chaganti, G. Bosl, 1998, The Journal of urology.

Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center

C. Sima, V. Rusch, M. Bains, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acute chest pain syndrome during bleomycin infusions

M. Kris, G. Bosl, D. White, 1987, Cancer.

In vivo differentiation and genomic evolution in adult male germ cell tumors

A. Olshen, V. Reuter, J. Korkola, 2008, Genes, chromosomes & cancer.

Altering the Natural History of Surgical Relapse in Testicular Cancer: Suboptimal Surgery and Pneumoperitoneum.

G. Bosl, D. Feldman, J. Sheinfeld, 2019, European urology.

Decreased progesterone binding and attenuated progesterone action in cultured human breast carcinoma cells treated with epidermal growth factor.

W. Blattner, J. Nadeau, C. Pui, 1988, Cancer research.

Evaluation of lymph node counts in primary retroperitoneal lymph node dissection

V. Reuter, R. Motzer, D. Bajorin, 2010, Cancer.

Gene expression-based classification of nonseminomatous male germ cell tumors

A. Olshen, V. Reuter, J. Korkola, 2005, Oncogene.

miR-18b and miR-518b Target FOXN1 during epithelial lineage differentiation in pluripotent cells.

M. Tomishima, V. Thodima, R. Chaganti, 2014, Stem cells and development.

Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

M. Bains, R. Motzer, D. Bajorin, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors

L. Schwartz, J. Bacik, M. Mazumdar, 2004, Investigational new drugs.

The role of a geriatrician in a cancer center.

G. Bosl, A. Shahrokni, K. Alexander, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel in germ cell cancer.

L. Schwartz, R. Motzer, T. Chou, 1995, Seminars in oncology.

Double-blind, randomized trial of granulocyte-colony stimulating factor (GCSF) versus (v.) placebo during postoperative radiation (RT) for advanced resectable squamous cell head and neck cancer (SCCHN): Impact on mucositis.

M. Zelefsky, G. Bosl, S. Lake, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up.

H. Scher, D. Bajorin, G. Bosl, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical features, presentation, and tolerance of platinum‐based chemotherapy in germ cell tumor patients 50 years of age and older

R. Motzer, M. Voss, G. Bosl, 2013, Cancer.

Germ Cell Tumors Cytogenetic Analysis of 124 Prospectively Ascertained Male Updated

V. Reuter, R. Chaganti, G. Bosl, 2006 .

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

M. Gonen, M. Shah, G. Schwartz, 2009, Clinical Cancer Research.

Serum Tumor Marker Half-Life during Chemotherapy in Patients with Germ Cell Tumors

G. Bosl, M. Head, G.J. Bosl, 1994, The International journal of biological markers.

Phase II trial of mitoguazone in patients with refractory germ cell tumors.

G. Bosl, H. Chun, 1985, Cancer treatment reports.

Optimal management of clinical stage I testis cancer: one size does not fit all.

G. Bosl, R. de Wit, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of risk in metastatic testis carcinoma: impact on treatment.

N. Geller, D. Bajorin, G. Bosl, 1991, Urologia internationalis.

Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.

R. Motzer, D. Sjoberg, D. Bajorin, 2015, Urology.

830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum

R. Motzer, B. Carver, G. Bosl, 2007 .